The American biotechnology company Gilead Sciences announced today that its drug Trodelvy (sacituzumab govitecan-hziy) has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a Category 1 preferred treatment option for patients with metastatic breast cancer (specific type) that is PD-L1 negative (CPS <10) and without germline BRCA1/2 PV. This recommendation represents the highest level of treatment advice currently available for such patients.

Furthermore, the guidelines also indicate that Trodelvy can be used in combination with the immunotherapy Keytruda (pembrolizumab) as a Category 2A preferred regimen, specifically for patients with first-line metastatic breast cancer (specific PD-L1 positive type) whose tumors test positive for PD-L1 (CPS ≥10). This combination therapy offers a new treatment option for this specific patient population, potentially improving their prognosis and quality of life.

Gilead Sciences stated that the updated NCCN guidelines represent an important milestone for patients. Metastatic breast cancer is one of the most aggressive cancer types, and historically, specific subtypes have been difficult to treat. The inclusion of Trodelvy in the guidelines will provide more effective treatment options for these patients, addressing their urgent therapeutic needs.